Roche comes up short in its attempt to hold off generic competition to Esbriet
Roche’s blockbuster idiopathic pulmonary fibrosis drug Esbriet brings in more than $1 billion a year — and the Swiss pharma giant would like to keep it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
